Amoxicillin-Clavulanate Dosage and Administration

Pediatric Dosing

• The American Academy of Allergy and Clinical Immunology recommends a dosage of 45 mg/kg/day every 12 hours or 40 mg/kg/day every 8 hours for children ≥12 weeks with more severe infections 1
• For children ≥12 weeks with less severe infections, the recommended dosage is 25 mg/kg/day every 12 hours or 20 mg/kg/day every 8 hours 1
• A high-dose formulation of 90 mg/kg/day of amoxicillin with 6.4 mg/kg/day of clavulanate in two divided doses may be considered for certain infections 2

Special Considerations

• The American Academy of Otolaryngology-Head and Neck Surgery suggests considering higher doses (such as 875 mg/125 mg or 2000 mg/125 mg) when antibiotic resistance is likely, including recent antibiotic use, contact with healthcare environment, prior antibiotic therapy failure, or high prevalence of resistant bacteria in the community 3
• Higher doses may also be considered for moderate to severe infections, such as frontal or sphenoidal sinusitis, or for patients with comorbid conditions, immunocompromised status, or age >65 years 3

Duration of Therapy

• The typical course for respiratory infections is 7-10 days 1
• For sinusitis, the recommended duration is 10-14 days or until the patient is symptomatically improved for 7 days 1
• For uncomplicated urinary tract infections, the recommended duration is 3-7 days 4

Amoxicillin-Clavulanate Dosing for Pediatric Patients

Monitoring and Safety Considerations

• Evaluate clinical response within 48-72 hours of initiating therapy, as recommended by the Clinical Infectious Diseases guideline 5

Therapeutic Dosage of Co-Amoxiclav (Amoxicillin/Clavulanate) for Respiratory Infections

Adult Dosing

• For moderate-severe COPD exacerbations without risk factors for Pseudomonas aeruginosa, the European Respiratory Society recommends Co-amoxiclav as a first-line treatment 6
• For intra-abdominal infections with adequate source control, the World Society of Emergency Surgery recommends Amoxicillin/Clavulanate 2 g/0.2 g every 8 hours in non-critically ill, immunocompetent patients 7

Pediatric Dosing

• For acute bacterial rhinosinusitis in children, the American Academy of Otolaryngology-Head and Neck Surgery recommends Amoxicillin/clavulanate at 90 mg/6.4 mg/kg per day 8

Specific Indications

• For acute otitis media, the American Academy of Otolaryngology-Head and Neck Surgery recommends High-dose amoxicillin-clavulanate in children who have received amoxicillin in the previous 30 days or with otitis-conjunctivitis 9

Common Pitfalls and Caveats

• In areas with high prevalence of penicillin-resistant S. pneumoniae, higher doses may be necessary, according to the American Academy of Otolaryngology-Head and Neck Surgery and the European Respiratory Society 8, 10

Co-Amoxiclav Therapeutic Dosing for Respiratory Tract Infections

Adult Dosing Regimens

• The high-dose regimen of 2000 mg/125 mg twice daily achieves adequate serum concentrations to eradicate penicillin-resistant Streptococcus pneumoniae with amoxicillin MICs up to 4-8 mg/L, and is recommended when antibiotic resistance is likely 11

Duration of Therapy

• The recommended duration of therapy for uncomplicated acute bacterial rhinosinusitis in adults is 5-7 days 12

Pediatric Dosing

• The high-dose pediatric formulation of 90 mg/kg/day of amoxicillin with 6.4 mg/kg/day of clavulanate in two divided doses is recommended for acute bacterial rhinosinusitis and resistant infections in children 13
• The recommended duration of therapy for children with acute bacterial rhinosinusitis is 10-14 days, which is longer than the recommended duration for adults 12

Critical Dosing Considerations

• Avoid underdosing in areas with high penicillin-resistant S. pneumoniae prevalence, and use high-dose formulations (2000 mg/125 mg twice daily for adults or 90 mg/kg/day for children) 11
• Evaluate clinical response within 48-72 hours of initiating therapy to determine the need for alternative management 12

Amoxicilina-Ácido Clavulánico Dosing Recommendations

Introduction to Dosing

• The American Academy of Otolaryngology-Head and Neck Surgery recommends a standard dose of Amoxicilina-Ácido Clavulánico 875/125 mg twice daily for adults, but in situations of probable bacterial resistance or severe infections, a high dose of 2000/125 mg twice daily should be considered 14

Patient Factors Influencing Dose Selection

• The American Academy of Otolaryngology-Head and Neck Surgery suggests that factors such as use of antibiotics in the last month, close contact with healthcare personnel or hospital environment, previous antibiotic therapy failure, high prevalence of resistant bacteria in the community, smoking, or close contact with children in daycare centers may require the high dose of 2000/125 mg twice daily 14
• Patients with comorbidities such as diabetes mellitus, chronic heart, lung, liver, or kidney disease may require the high dose of 2000/125 mg twice daily, as recommended by the American Academy of Otolaryngology-Head and Neck Surgery and the American Journal of Respiratory and Critical Care Medicine 14, 15

Infection-Specific Treatment Duration

• The American Journal of Respiratory and Critical Care Medicine recommends a treatment duration of 7-10 days for community-acquired pneumonia 15

Critical Dosage Considerations

• In areas with high prevalence of Streptococcus pneumoniae resistant to penicillin (>10%), the American Academy of Otolaryngology-Head and Neck Surgery always recommends using the high dose of 2000/125 mg twice daily to achieve adequate serum concentrations to eradicate strains with amoxicilina MIC up to 4-8 mg/L 14

Co-amoxiclav Dosing Regimens

Pediatric Dosing

• The American Academy of Pediatrics recommends standard dosing by age for oral suspension: 0.266 ml/kg of 125/31 suspension three times daily, or 2.5 ml three times daily for children from birth to 1 year, 5 ml of 125/31 suspension three times daily for children from 1-6 years, 5 ml of 250/62 suspension three times daily for children from 7-12 years, and 1 tablet (250/125) three times daily for children from 12-18 years 16, 17, 18
• The Infectious Diseases Society of America recommends intravenous dosing of 30 mg/kg three times daily IV for all pediatric ages, with dose frequency increased to 4 times daily in severe infections for patients >3 months 16, 17, 18

Adult Dosing

• The American College of Chest Physicians recommends 625 mg three times daily orally for hospital-treated non-severe pneumonia 19, 18
• The Infectious Diseases Society of America recommends switching from IV to oral as soon as clinically appropriate, with co-amoxiclav 625 mg three times daily as an alternative to oral cephalosporins 19, 18

Duration of Therapy

• The American Thoracic Society recommends a duration of therapy of 7-10 days, may need up to 14 days depending on clinical response, for community-acquired pneumonia 16

Critical Dosing Considerations

• The American Academy of Pediatrics and the Infectious Diseases Society of America recommend doubling doses in severe infections for both oral and IV formulations 16

Augmentin (Amoxicillin‑Clavulanate) Dosing Recommendations for Adults with Respiratory Infections

Standard Dosing Regimen

• For adults with normal renal function and no penicillin allergy, the American Academy of Otolaryngology‑Head and Neck Surgery (AAO‑HNS) recommends Augmentin 875 mg/125 mg taken twice daily for a 7‑day course for most respiratory tract infections. 20
• A 7‑day course of Augmentin is clinically equivalent to a 10‑day course for most respiratory infections, providing comparable cure rates while producing fewer adverse events. 20

High‑Dose Regimen Indications

• When any of the following risk factors for antimicrobial resistance are present, the AAO‑HNS advises escalating to Augmentin 2000 mg/125 mg twice daily for 7 days:

These indications are based on AAO‑HNS guidance. 20

Duration of Therapy by Infection Type

• For acute bacterial rhinosinusitis, a 5‑ to 7‑day course of Augmentin is as effective as a 10‑day course. 20

Clinical Efficacy of High‑Dose Therapy

• In patients with the above resistance risk factors, high‑dose Augmentin (2000 mg/125 mg BID) achieves a predicted clinical efficacy of 90‑92 %, compared with 83‑88 % for the standard 875 mg/125 mg BID regimen. 20

Safety Profile

• Gastro‑intestinal adverse events occur in approximately 15‑40 % of patients receiving Augmentin, but discontinuation of therapy is rarely required. 20

IV Augmentin Dosing Guidelines

Adult Intravenous Dosing

• For adults with moderate to severe infections, administer IV Augmentin 1.2 g (1000 mg amoxicillin + 200 mg clavulanate) every 6–8 hours. This recommendation is based on clinical infectious disease guidance for community‑acquired intra‑abdominal infections in non‑critically ill, immunocompetent patients with adequate source control. 21

• For biliary infections following cholecystectomy, discontinue antimicrobial therapy within 24 hours unless there is evidence of infection extending beyond the gallbladder wall. 21

• For intra‑abdominal infections with adequate source control, a treatment duration of 4–7 days is typical, guided by the patient’s clinical response. 21

Pediatric Intravenous Dosing

• In children with moderate infections, give IV Augmentin at 30 mg/kg (amoxicillin component) every 6–8 hours. This dosing applies across pediatric ages for most moderate infections. 21

• For severe infections or when undrained abscesses are possible, increase the amoxicillin component up to 200 mg/kg/day, divided every 6 hours. This higher‑dose regimen aims to achieve adequate exposure in severe pediatric disease. 21

Renal Impairment Dosing Adjustments

Adults

• When creatinine clearance is 10–30 mL/min, reduce the dosing frequency to every 12 hours or decrease the dose by 50 %. This adjustment helps avoid drug accumulation in moderate renal impairment. 22

• When creatinine clearance is < 10 mL/min, reduce the dosing frequency to every 24 hours or decrease the dose by 75 %. This provides safer exposure in severe renal impairment. 22

• Patients receiving hemodialysis require supplemental IV Augmentin dosing after each dialysis session. This compensates for drug removal during dialysis. 22

Pediatrics

• For children with reduced renal function, apply proportional dose reductions based on estimated creatinine clearance, acknowledging that specific pediatric renal dosing guidelines are limited. This pragmatic approach mirrors adult adjustments. 21